Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Denali Therapeutics Inc.

www.denalitherapeutics.com

Latest From Denali Therapeutics Inc.

Parkinson’s Disease: Novel Science And Collaborations Fuel Progress

Novel therapeutic strategies for Parkinson’s disease have brought a renewed sense of optimism to those researching this neurodegenerative disorder. Numerous treatment avenues are being explored, including small molecules, gene therapy, cell therapy and medical devices to stimulate nerves deep in the brain. Digital also gets a look-in, being useful for analyzing gait and other symptoms, and addressing both mental and physical issues.

BioPharmaceutical Neurology

F-star CEO: Revamped Merck KGaA Pact Is First Step In New Corp Direction

F-star CEO tells Scrip reconfiguring biotech’s pact with Merck KGaA on oncology asset FS118 is UK group’s first big move towards a wholly owned portfolio strategy.

Commercial Deals

Biogen Stays Steady As Alzheimer’s Programs Falter

Still reeling from aducanumab’s failure in Phase III Alzheimer’s trial, Biogen management played up the company’s progress toward diversification and the promise of its pipeline. 
Sales & Earnings Biosimilars

AbCellera Finds Antibody Candidates Other Technologies Might Not

Emerging Company Profile: A platform research company, AbCellera is not developing any drugs, but has seen triple-digit revenue growth each year since 2015 via a model of discovering next-generation therapeutic antibody candidates for partners.

Platform Technologies Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
  • Therapeutic Areas
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Company Type
  • Start-Up
  • Parent & Subsidiaries
  • Denali Therapeutics Inc.
  • Senior Management
  • Ryan Watts, PhD, CEO
    Steve E Krognes, CFO
    Carole Ho, MD, CMO
    Alexander Schuth, MD, COO
  • Contact Info
  • Denali Therapeutics Inc.
    151 Oyster Point Blvd.
    South San Francisco, CA 94080
    USA
UsernamePublicRestriction

Register